S. Hodges

A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.

G. Weiss, D. V. Von Hoff, H. Burris, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.

D. V. Von Hoff, M. Villalona-Calero, L. Schaaf, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.

G. Weiss, D. V. Von Hoff, S. Hilsenbeck, 1998, Blood.

Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.

D. V. Von Hoff, M. Villalona-Calero, L. Schaaf, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea

G. Weiss, S. Hilsenbeck, D. V. Hoff, 1998 .

927 A phase I and bioavailability study of oral topotecan

H. Burris, D. V. Hoff, J. Kuhn, 1995 .

A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia.

C. Schiffer, C. Carter, E. Lee, 1993, Leukemia.

A Phase I Study of the Potent Hsp90 Inhibitor STA-9090 Administered Twice Weekly In Subjects with Hematologic Malignancies

D. DeAngelo, M. Frattini, M. Heaney, 2010 .